Newswire (Published: Thursday, September 26, 2019, 7:11:00 AM CDT, Received: Thursday, September 26, 2019, 7:51:21 AM CDT)
Word Count: 630
Men who are diagnosed with low-risk prostate cancer usually opt for active surveillance a monitoring of their cancer over time without undergoing treatments that would cause side effects. In many men, the cancer never grows and poses no threat, but in others, the cancer begins to grow and treatment is necessary.
The hope is that the drug which uses the patients own immune cells and doesnt cause side effects will attack and eliminate the cancer or keep it from changing over time.
Were very excited about this clinical trial, said Dr.
The drug, called Provenge, already is approved by the
In the clinical trial, men who are randomized to receive Provenge will have their blood drawn, just as if they were donating blood. The immune cells are filtered out, and the rest of the blood is returned to the patient. The patients cells are then shipped to a company out of state, where they are infused with a molecule that provokes an immune response specific to prostate cancer, coupled with a growth factor that stimulates the cells to grow. The cells are shipped back to
Basically, its activating a persons cells against prostate cancer and prompting them to recognize the cancer, Stratton said. Once theyve been activated, our thought is that they will go to the prostate and either fight the cancer or keep it from growing.
Because Provenge uses the patients own cells, most patients have little to no side effects, Stratton said. The immune cells are not genetically altered, making the treatment safe and well tolerated.
Thats the whole point of active surveillance to minimize the risk of side effects that come with treatment like radiation therapy, he said. With Provenge, were not manipulating the cells were only doing what would happen naturally if the cells were to recognize prostate cancer.
If the clinical trial proves the drug to be successful in low-risk patients, it also will benefit patients mental outlook, Stratton said. Most patients appreciate active surveillance because they can avoid treatment, but it can also lead to an unsettling feeling of not doing anything to keep the cancer in check, he said.
Patients love the idea of active surveillance, but theres also a natural feeling of wanting to do something to address the cancer, he said. We think this drug is something that will activate their immune system against the cancer, but their quality of life will stay the same.
Urologic oncologist Dr.
Weve made major contributions to national clinical trials with our prostate cancer patients, who are brave and willing to allow us to try to move the science forward, Cookson said.